Literature DB >> 11550122

Successful treatment of disseminated Mycobacterium chelonae infection with linezolid.

B A Brown-Elliott1, R J Wallace, R Blinkhorn, C J Crist, L B Mann.   

Abstract

We describe a 57-year-old man with steroid-dependent myasthenia gravis and progressive ulcerating leg nodules due to clarithromycin-resistant Mycobacterium chelonae. The patient was successfully treated with linezolid.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11550122     DOI： 10.1086/322523

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  17 in total

Review 1.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

2.  In vitro activities of the novel oxazolidinones DA-7867 and DA-7157 against rapidly and slowly growing mycobacteria.

Authors:  Lucio Vera-Cabrera; Barbara A Brown-Elliott; Richard J Wallace; Jorge Ocampo-Candiani; Oliverio Welsh; Sung Hak Choi; Carmen A Molina-Torres
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

3.  Mycobacterium chelonae hand infection after steroid injection in a patient with rheumatoid arthritis receiving long-term linezolid therapy.

Authors:  Jens Steen Olesen; Mikala Wang; Christian Wejse
Journal:  BMJ Case Rep       Date:  2017-01-30

4.  In Vitro Susceptibility Testing of Tedizolid against Nontuberculous Mycobacteria.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  J Clin Microbiol       Date:  2017-03-22       Impact factor: 5.948

5.  In vitro activity of linezolid against slowly growing nontuberculous Mycobacteria.

Authors:  Barbara A Brown-Elliott; Christopher J Crist; Linda B Mann; Rebecca W Wilson; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

6.  Intrapulmonary pharmacokinetics of linezolid.

Authors:  John E Conte; Jeffrey A Golden; Juliana Kipps; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

7.  Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria.

Authors:  Barbara A Brown-Elliott; Richard J Wallace; Christopher J Crist; Linda Mann; Rebecca W Wilson
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

8.  Infection of total hip prosthesis by Mycobacterium tuberculosis and Mycobacterium chelonae in a patient with rheumatoid arthritis.

Authors:  Alex Brown; Peter Grubbs; Anne-Barbara Mongey
Journal:  Clin Rheumatol       Date:  2007-11-23       Impact factor: 2.980

9.  High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan.

Authors:  Shun-Cheng Yang; Po-Ren Hsueh; Hsin-Chih Lai; Lee-Jene Teng; Li-Min Huang; Jong-Min Chen; Shu-Kuan Wang; Der-Chuen Shie; Shen-Wu Ho; Kwen-Tay Luh
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

Review 10.  Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.